Press Announcements > FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

Press Announcements > FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence







FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film, which is also approved in both brand name and generic versions and in various strengths.